Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 179 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

 		Relapsing Multiple Sclerosis Phase1, Phase2 Australia
Switzerland 		NCT06617793

ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

 		Relapsing Remitting Multiple Sclerosis (RRMS) Phase4 Canada NCT06733922

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

 		Metastatic Castration-Resistant Prostate Cancer Phase1 Netherlands
United Kingdom
United States 		NCT06531499

Phase 2 Study of Rapcabtagene Autoleucel in Myositis

 		Idiopathic Inflammatory Myopathies Phase2 Israel
Japan
United States 		NCT06665256

A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

 		Primary Hypercholesterolemia, Mixed Dyslipidemia Phase4 India NCT06386419

Specified Drug-use Surveillance of Fabhalta Capsules

 		Paroxysmal Nocturnal Hemoglobinuria Japan NCT06606314

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

 		Relapsing Multiple Sclerosis Phase3 United States NCT03650114

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

 		Healthy Volunteers, Pulmonary Arterial Hypertension Phase1, Phase2 United States NCT06649110

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

 		Systemic Lupus Erythematosus, SLE Phase1 Spain NCT06335979

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

 		Sickle Cell Disease Phase3 United States NCT06439082